[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zhang longjiang,MD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":72},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100580876","serial-coronary-cta-based-plaque-progression-detection-for-management-of-coronary-heart-disease-100580876",false,"NCT06843005","Serial Coronary CTA-based Plaque Progression Detection for Management of Coronary Heart Disease","Serial Coronary CTA-based Plaque Progression Detection for Management of Coronary Heart Disease: a Randomised Controlled Trial","SUCCESS","Inclusion Criteria:\n\n1. Age between 18 and 80 years old;\n2. Known patients with non-obstructive coronary artery disease (disease duration ≥2 years);\n3. Patients who agree to undergo follow-up CCTA examinations and cooperate in completing follow-up observations.\n\nExclusion Criteria:\n\n1. Patients who have experienced ACS or PCI\u002FCABG;\n2. Patients who have experienced adverse cardiovascular and cerebrovascular events;\n3. Patients who have undergone follow-up CCTA or DSA examinations before enrollment;\n4. Patients with severe hepatic and renal dysfunction;\n5. Patients with contraindications to CCTA examinations;\n6. Patients with poor initial CCTA image quality or data loss.","ALL","18 Years","80 Years",{"count":21,"type":22},3100,"ESTIMATED","INTERVENTIONAL",[25],"NA","The primary objective of this study is to evaluate whether a management strategy based on coronary computed tomography angiography (CCTA) for patients with non-obstructive coronary artery disease can improve the LDL-C target achievement rate compared to a traditional management strategy without follow-up CCTA, thereby reducing the incidence of major adverse cardiovascular and cerebrovascular events over a 3 years period, including all-cause mortality, myocardial infarction, ischemia driven revascularation and stroke.",[28,29,30,31],"Major Adverse Cardiovascular Events (MACE)","Prevention","Coronary Artery Disease(CAD)","CT Angiography","RECRUITING","2026-03-19",{"date":35,"type":36},"2026-03-24","ACTUAL",{"date":38,"type":36},"2025-02-28",{"date":40,"type":22},"2028-12-30",{"name":42,"class":43},"Zhang longjiang,MD","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":44},"100494970","role-of-coronary-cta-on-lipid-management-and-risk-factors-control-in-an-asymptomatic-chinese-population-100494970","NCT05725096","Role of Coronary CTA on Lipid Management and Risk Factors Control in an Asymptomatic Chinese Population","Role of the Screening with Coronary Computed Tomography Angiography on Lipid Management and Risk Factors Control in an Asymptomatic Chinese Population: a Community-based, Prospective Randomised Trial","RESPECT2","Inclusion Criteria:\n\n1. Nanjing residents who have no plans to leave in the next 5 years\n2. Aged from 40 to 69 years\n3. Free of any known clinically cardiovascular disease Able to comprehend and sign an informed consent form\n\nExclusion Criteria:\n\n1. Serious liver dysfunction, defined as AST or ALT \\> 3 times the normal upper limit\n2. Chronic kidney disease (CKD) \\> stage 4, defined as eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2\n3. Prior CCTA or invasive coronary angiography within the last 5 years\n4. Any contraindications for CCTA\n5. Previous use of statin or non-statin lipid-lowering medication (such as ezetimibe, PCSK9 inhibitor and XueZhiKang)\n6. Life expectancy \\\u003C 3 years\n7. Other reasons the researcher deems inappropriate to attend","40 Years","69 Years",{"count":56,"type":22},3400,[25],"The primary objective of this study is to determine whether coronary computed tomography angiography (CCTA) -based coronary heart disease(CHD) prevention strategy improves lipid-lowering treatment and cardiovascular risk factor control compared with traditional CHD prevention strategy, guided by a cardiovascular risk score.",[60,61,62,63],"Statin","Cardiovascular Risk Factors","Primary Prevention","Adherence, Medication","2024-11-25",{"date":66,"type":36},"2024-11-26",{"date":68,"type":36},"2023-06-28",{"date":70,"type":22},"2027-06",{"name":42,"class":43},""]